Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
FDA Orange Book
0
Canada
0
Australia
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. Ago 178
2. Ago-178
3. Ago178
4. N-(2-(7-methoxy-1-naphthyl)ethyl)acetamide
5. S 20098
6. S-20098
7. S20098
8. Thymanax
9. Valdoxan
1. 138112-76-2
2. Thymanax
3. Valdoxan
4. N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide
5. N-(2-(7-methoxynaphthalen-1-yl)ethyl)acetamide
6. S20098
7. S-20098
8. Agomelatine [inn]
9. Melitor
10. Ago-178
11. S 20098
12. Acetamide, N-[2-(7-methoxy-1-naphthalenyl)ethyl]-
13. N-(2-(7-methoxy-1-naphthyl)ethyl)acetamide
14. N-(2-(7-methoxynaphth-1-yl)ethyl)acetamide
15. N-(2-(7-methoxy-1-naphthalenyl)ethyl)acetamide
16. Chembl10878
17. 137r1n49ad
18. N-[2-(7-methoxy-1-naphthalenyl)ethyl]acetamide
19. Agomelatine (inn)
20. Ncgc00253646-01
21. N-[2-(7-methoxy-1-naphthyl)ethyl]acetamide
22. Acetamide, N-(2-(7-methoxy-1-naphthalenyl)ethyl)-
23. N-[2-(7-methoxy-naphthalen-1-yl)-ethyl]-acetamide
24. Ago 178
25. Valdoxan (tn)
26. Unii-137r1n49ad
27. Ago178
28. N-[2-(7-methoxynaphth-1-yl)ethyl]acetamide
29. Sr-01000944938
30. Agomelatine [inn:ban]
31. Ago178c
32. Agomelatine-[d4]
33. Awy
34. Agomelatine- Bio-x
35. Mfcd00916659
36. Agomelatine [mi]
37. Agomelatine [mart.]
38. Dsstox_cid_31431
39. Dsstox_rid_97317
40. Dsstox_gsid_57642
41. Agomelatine [who-dd]
42. Gtpl198
43. Mls006011913
44. Schembl114476
45. Agomelatine [ema Epar]
46. Zinc5608
47. Dtxsid3057642
48. Agomelatine, >=98% (hplc)
49. Chebi:134990
50. Bcpp000421
51. Hms3604n09
52. Hms3648g18
53. Hms3654b07
54. Hms3884a07
55. Bcp02084
56. Tox21_113772
57. Bbl029084
58. Bdbm50035179
59. Pdsp1_001305
60. Pdsp1_001784
61. Pdsp2_001289
62. Pdsp2_001767
63. S1243
64. Stl237728
65. Akos005145681
66. Ac-3395
67. Bcp9000250
68. Ccg-221950
69. Cs-0740
70. Db06594
71. Ks-1247
72. Sb19508
73. Ncgc00253646-10
74. Ba167079
75. Hy-17038
76. Smr002530056
77. Am20090763
78. B2262
79. Cas-138112-76-2
80. Ft-0657383
81. Sw219177-1
82. A19445
83. D02578
84. Ab01274769-01
85. Ab01274769_02
86. 112a762
87. L000528
88. Q395229
89. Q-102507
90. Sr-01000944938-1
91. Sr-01000944938-3
92. F0001-2383
93. (4-chlorophenyl)-[(9h-fluoren-9-ylmethoxycarbonylamino)]-aceticacid
94. N-[2-(7-methoxy-naphthalen-1-yl)-ethyl]-acetamide(agomelatine)
Molecular Weight | 243.30 g/mol |
---|---|
Molecular Formula | C15H17NO2 |
XLogP3 | 2.7 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 4 |
Exact Mass | 243.125928785 g/mol |
Monoisotopic Mass | 243.125928785 g/mol |
Topological Polar Surface Area | 38.3 Ų |
Heavy Atom Count | 18 |
Formal Charge | 0 |
Complexity | 280 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Agomelatine is indicated to treat major depressive episodes in adults.
Treatment of major depressive episodes in adults.
Treatment of major depressive episodes in adults.
Treatment of major depressive episodes
Agomelatine resynchronises circadian rhythms in animal models of delayed sleep phase syndrome and other circadian rhythm disruptions. It increases noradrenaline and dopamine release specifically in the frontal cortex and has no influence on the extracellular levels of serotonin. Agomelatine has shown an antidepressant-like effect in animal depression models, (learned helplessness test, despair test, and chronic mild stress) circadian rhythm desynchronisation, and in stress and anxiety models. In humans, agomelatine has positive phase shifting properties; it induces a phase advance of sleep, body temperature decline and melatonin onset. Controlled studies in humans have shown that agomelatine is as effective as the SSRI antidepressants paroxetine and sertraline in the treatment of major depression
Hypnotics and Sedatives
Drugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. (See all compounds classified as Hypnotics and Sedatives.)
N06AX22
N06AX22
N06AX22
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
N - Nervous system
N06 - Psychoanaleptics
N06A - Antidepressants
N06AX - Other antidepressants
N06AX22 - Agomelatine
Absorption
Bioavailability is less than 5%.
Hepatic (90% CYP1A2 and 10% CYP2C9).
<2 hours
The novel antidepressant agent, agomelatine, behaves as an agonist at melatonin receptors (MT1 and MT2) and as an antagonist at serotonin (5-HT)(2C) receptors.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 38958
Submission : 2023-09-27
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26965
Submission : 2013-03-08
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 27206
Submission : 2013-06-21
Status : Active
Type : II
Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2023-10-05
Registration Number : 434-59-ND
Manufacturer Name : MSN Pharmachem Private Limit...
Manufacturer Address : Plot. No. 182 to 186, 192-A, 193 to 197 & 212/A,B,C,D, Phase-II, IDA Pashamylaram, Pa...
Registrant Name : Korea Serviette Co., Ltd.
Registration Date : 2010-05-27
Registration Number : Su3056-1-ND
Manufacturer Name : ORIL Industry
Manufacturer Address : 13, rue Auguste Desgenetais, BOLBEC, 76210, France
Registrant Name : Hiple Co., Ltd.
Registration Date : 2016-12-02
Registration Number : Su50-1-ND
Manufacturer Name : Symed Labs Limited
Manufacturer Address : UNIT-II, Plot No. 25/B, Phase-III, IDA, Jeedimetla (Village), Quthbullapur (Mandal), ...
Registrant Name : Pharmapia Co., Ltd.
Registration Date : 2021-04-16
Registration Number : Su50-1-ND(1)
Manufacturer Name : Symed Labs Limited
Manufacturer Address : Plot No.25/B, Phase-III, IDA Jeedimetla Hyderabad-500 055, Telangana State, India
NDC Package Code : 50370-0041
Start Marketing Date : 2013-06-21
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 50370-0053
Start Marketing Date : 2016-02-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 64220-223
Start Marketing Date : 2024-07-30
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
About the Company : Biophore, founded in 2007, has established itself as a reliable partner in the development and manufacturing of niche and complex pharmaceutical products. With 4 USFDA and EU-appro...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...
About the Company : Beijing Lunarsun pharma is a professional manufacturer of API and intermediates. The factory is approved by US FDA. According to EU and US FDA's requirement, we supply following AP...
About the Company : We have been supporting the pharmaceutical and biopharmaceutical industries with drug development for over 30 years, assisting our clients in developing and bringing new drugs to m...
About the Company : Enaltec Labs was established in 2006 by a group of young & experienced professionals with the specific objective to develop & produce complex, small volume, technology driven produ...
About the Company : Globofarm International Pvt Ltd is a well-informed, highly efficient, Swiftly functioning competitive sourcing entity. We serve private, institutional, and corporate clients worldw...
About the Company : Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Ex...
About the Company : Mehta API Pvt Ltd engaged in manufacturing and marketing of APIs & Advance Drug Intermediates.... Globally. Mehta Api has been inordinately proud of its achievements since its ince...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Global Sales Information
Market Place
ANALYTICAL
ABOUT THIS PAGE
53
PharmaCompass offers a list of Agomelatine API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Agomelatine manufacturer or Agomelatine supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Agomelatine manufacturer or Agomelatine supplier.
PharmaCompass also assists you with knowing the Agomelatine API Price utilized in the formulation of products. Agomelatine API Price is not always fixed or binding as the Agomelatine Price is obtained through a variety of data sources. The Agomelatine Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A valdoxan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of valdoxan, including repackagers and relabelers. The FDA regulates valdoxan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. valdoxan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of valdoxan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A valdoxan supplier is an individual or a company that provides valdoxan active pharmaceutical ingredient (API) or valdoxan finished formulations upon request. The valdoxan suppliers may include valdoxan API manufacturers, exporters, distributors and traders.
click here to find a list of valdoxan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A valdoxan DMF (Drug Master File) is a document detailing the whole manufacturing process of valdoxan active pharmaceutical ingredient (API) in detail. Different forms of valdoxan DMFs exist exist since differing nations have different regulations, such as valdoxan USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A valdoxan DMF submitted to regulatory agencies in the US is known as a USDMF. valdoxan USDMF includes data on valdoxan's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The valdoxan USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of valdoxan suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a valdoxan Drug Master File in Korea (valdoxan KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of valdoxan. The MFDS reviews the valdoxan KDMF as part of the drug registration process and uses the information provided in the valdoxan KDMF to evaluate the safety and efficacy of the drug.
After submitting a valdoxan KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their valdoxan API can apply through the Korea Drug Master File (KDMF).
click here to find a list of valdoxan suppliers with KDMF on PharmaCompass.
A valdoxan written confirmation (valdoxan WC) is an official document issued by a regulatory agency to a valdoxan manufacturer, verifying that the manufacturing facility of a valdoxan active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting valdoxan APIs or valdoxan finished pharmaceutical products to another nation, regulatory agencies frequently require a valdoxan WC (written confirmation) as part of the regulatory process.
click here to find a list of valdoxan suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing valdoxan as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for valdoxan API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture valdoxan as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain valdoxan and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a valdoxan NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of valdoxan suppliers with NDC on PharmaCompass.
valdoxan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of valdoxan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right valdoxan GMP manufacturer or valdoxan GMP API supplier for your needs.
A valdoxan CoA (Certificate of Analysis) is a formal document that attests to valdoxan's compliance with valdoxan specifications and serves as a tool for batch-level quality control.
valdoxan CoA mostly includes findings from lab analyses of a specific batch. For each valdoxan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
valdoxan may be tested according to a variety of international standards, such as European Pharmacopoeia (valdoxan EP), valdoxan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (valdoxan USP).